References
- Stech J, Garn H, Herwig A et al. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. J. Infect. Dis.204(10), 1483–1490 (2011).
- Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert. Rev. Vaccin.8(4), 383–389 (2009).
- Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine26(Suppl. 4), D41–D44 (2008).
- Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann. Rev. Biochem.69, 531–569 (2000).
- Hensley SE, Das SR, Bailey AL et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science326(5953), 734–736 (2009).
- Ibanez LI, De Filette M, Hultberg A et al. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J. Infect. Dis.203(8), 1063–1072 (2011).
- Kido H, Yokogoshi Y, Sakai K et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J. Biol. Chem.267(19), 13573–13579 (1992).
- Klenk HD, Rott R, Orlich M, Blodorn J. Activation of influenza A viruses by trypsin treatment. Virology68(2), 426–439 (1975).
- Stieneke-Grober A, Vey M, Angliker H et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J.11(7), 2407–2414 (1992).
- Lee MG, Kim KH, Park KY, Kim JS. Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses. Arch. Virol.141(10), 1979–1989 (1996).
- Li WC, Shih SR, Huang YC et al. Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J. Clin. Virol.42(1), 45–51 (2008).
- Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine28(9), 2149–2156 (2010).
- Bodewes R, Kreijtz JH, Rimmelzwaan GF. Yearly influenza vaccinations: a double-edged sword? Lancet Infect. Dis.9(12), 784–788 (2009).
- Hoft DF, Babusis E, Worku S et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis.204(6), 845–853 (2011).
- Castrucci MR, Kawaoka Y. Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal residue of M2 protein. J. Virol.69(5), 2725–2728 (1995).
- Talon J, Salvatore M, O’Neill RE et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl Acad. Sci. USA97(8), 4309–4314 (2000).
- Bottcher E, Freuer C, Steinmetzer T, Klenk HD, Garten W. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine27(45), 6324–6329 (2009).
Website
- BRENDA. The comprehensive enzyme information system. www.brenda-enzymes.org/index.php4